Badran Omar, Campisi-Pinto Salvatore, Amna Mahmoud Abu, Turgeman Ilit, Yosef Samih, Bar-Sela Gil
Department of Oncology, Emek Medical Center, Afula, Israel.
Research Authority, Emek Medical Center, Afula, Israel.
Front Oncol. 2024 Apr 24;14:1337521. doi: 10.3389/fonc.2024.1337521. eCollection 2024.
This study investigates breast cancer survival rates between 2000 and 2022 in northern Israel, focusing on ethnicity, socioeconomic status, age at diagnosis, and the Charlson Comorbidity Index. Analyzing data from Clalit Health Services, we studied 8,431 breast cancer patients (6,395 Jewish, 2,036 Arab). We compared five- and ten-year survival rates across different demographics. Ethnicity showed a minor impact on survival (OR 1.12, 95% CI: 0.93 - 1.35). Socioeconomic status had a significant effect, with a higher level of improving survival (OR 2.50, 95% CI: 2.04 - 3.08). Age was crucial; women 18-39 had better survival than 60-100, but no significant difference was found between the 18-39 and 40-59 age groups [OR (CI 0.90 - 1.53, p = 0.231)]. For the Charlson Comorbidity Index, women with scores of 3-10 showed lower survival compared to scores of 0 and 1-2. There was a notable improvement in five-year survival rates among patients aged 18-59 diagnosed from 2009-2018 (90.7%) compared to 2000-2008 (86.9%) (p = 0.0046), but not in patients aged 60-100. The study highlights that socioeconomic status, age, and comorbidity scores are significant in determining survival rates for breast cancer. The improvement in survival rates for younger patients diagnosed more recently reflects advancements in treatment and care. This research provides valuable insights into the factors affecting breast cancer survival rates, underscoring the role of socioeconomic status, age, and comorbidities while also highlighting the progress in breast cancer treatment over recent years.
本研究调查了2000年至2022年以色列北部乳腺癌的生存率，重点关注种族、社会经济地位、诊断时的年龄以及查尔森合并症指数。通过分析克拉利特健康服务中心的数据，我们研究了8431名乳腺癌患者（6395名犹太人，2036名阿拉伯人）。我们比较了不同人口统计学特征下的五年和十年生存率。种族对生存率的影响较小（比值比1.12，95%置信区间：0.93 - 1.35）。社会经济地位有显著影响，水平越高生存率改善越明显（比值比2.50，95%置信区间：2.04 - 3.08）。年龄至关重要；18至39岁的女性生存率高于60至100岁的女性，但18至39岁和40至59岁年龄组之间未发现显著差异[比值比（置信区间0.90 - 1.53，p = 0.231）]。对于查尔森合并症指数，得分3至10的女性生存率低于得分0和1至2的女性。与2000年至2008年（86.9%）相比，2009年至2018年诊断的18至59岁患者的五年生存率有显著提高（90.7%）（p = 0.0046），但60至100岁患者则没有。该研究强调，社会经济地位、年龄和合并症得分在确定乳腺癌生存率方面具有重要意义。近期诊断的年轻患者生存率的提高反映了治疗和护理方面的进步。本研究为影响乳腺癌生存率的因素提供了有价值的见解，强调了社会经济地位、年龄和合并症的作用，同时也突出了近年来乳腺癌治疗方面的进展。
